Heart failure is a growing burden and health concern, says SHA chief

heart failure health burden sha
Saudi Arabia

Heart failure is a growing burden and health concern, says SHA chief

RIYADH “” AstraZeneca, in collaboration with the Saudi Heart Association (SHA), revealed a new approved indication by the Saudi Ministry of Health and the Food and Drug Authority for Dapagliflozin, expanding its usage to patients with heart failure, ensuring they can access the right treatment as needed. Saudi Arabia is the first country in the GCC to provide such approval for the new indication. A webinar organized by AstraZeneca in partnership with Saudi Heart Association, led by Prof.Waleed AlHabeeb, Consultant Heart Failure Cardiologist and President of the Saudi Heart Association, Prof. Mark Petrie - Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK together with a wider group of experts. The key topic of discussion at the event was the global and local burden of heart failure, the challenges it poses to patients and developments in treatment options. Heart Failure, which is classified as a chronic disease, represents one of the most serious health concerns facing society today, currently affecting approximately 50 million people worldwide annually. More than 1% of the Saudi population is diagnosed with Heart Failure, with estimated incidence of more than 32,000 cases per year. Prof. Waleed AlHabeeb said,

Goldman Sachs says now’s the time to buy these 7 stocks

Tech stocks could get hit by rising rates but Goldman says these names in the sector are safe

Qatar Fund for Development signs agreement with vaccine alliance Gavi

Tuesday Sector Leaders: Oil & Gas Exploration & Production, Metals & Mining Stocks